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Abstract
AIM: To identify definitions of cytomegalovirus (CMV) 
infection and intestinal disease, in inflammatory bowel 
disease (IBD), to determine the prevalence associated 
with these definitions.
METHODS: We conducted a systematic review 
and interrogated PubMed, EMBASE and Cochrane 
for literature on prevalence and diagnostics of CMV 
infection and intestinal disease in IBD patients. As 
medical headings we used “cytomegalovirus” OR “CMV” 
OR “cytomegalo virus” AND “inflammatory bowel 
disease” OR “IBD” OR “ulcerative colitis” OR “colitis 
ulcerosa” OR “Crohn’s disease”. Both MeSH-terms and 
free searches were performed. We included all types of 
English-language (clinical) trials concerning diagnostics 
and prevalence of CMV in IBD.
RESULTS: The search strategy identified 924 citations, 
and 52 articles were eligible for inclusion. We identified 
21 different definitions for CMV infection, 8 definitions 
for CMV intestinal disease and 3 definitions for CMV 
reactivation. Prevalence numbers depend on used 
definition, studied population and region. The highest 
prevalence for CMV infection was found when using 
positive serum PCR as a definition, whereas for CMV 
intestinal disease this applies to the use of tissue PCR > 
10 copies/mg tissue. Most patients with CMV infection 
and intestinal disease had steroid refractory disease 
and came from East Asia.
CONCLUSION: We detected multiple different 
definitions used for CMV infection and intestinal disease 
in IBD patients, which has an effect on prevalence 
numbers and eventually on outcome in different trials.
Key words: Inflammatory bowel disease; Cyto-
megalovirus; Ulcerative colitis; Crohn’s disease; Sys-
tematic review
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The use of different definitions for cyto-
megalovirus (CMV) infection and CMV intestinal 
disease in inflammatory bowel disease (IBD) patients 
has great impact on the reported prevalence rates 
(definitions with highest prevalence: positive serum 
PCR (CMV infection) and tissue PCR > 10 copies/mg 
tissue (CMV intestinal disease)). In addition, prevalence 
rates depend on the studied population (highest 
prevalence: steroid refractory disease), and region 
(highest prevalence: East Asia). Our key message is 
not to develop more sensitive diagnostics to find CMV, 
but to organise a global consensus meeting on CMV 
in IBD to formulate one unified definition for clinically 
relevant CMV (intestinal) disease in IBD.
Römkens TEH, Bulte GJ,  Nissen LHC, Drenth JPH. 
Cytomegalovirus in inflammatory bowel disease: A systematic 
review. World J Gastroenterol 2016; 22(3): 1321-1330  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v22/i3/1321.
htm  DOI: http://dx.doi.org/10.3748/wjg.v22.i3.1321
INTRODUCTION
Cytomegalovirus (CMV) is a member of human 
herpesvirus family[1]. CMV infection is common 
and mostly asymptomatic in healthy people. Ser­
oprevalence data differ depending on the healthcare 
circumstances or immunocompetency of the host, but 
most studies give a seroprevalence of 40%­100% in 
adults[2­4], with the highest prevalence in non­western 
countries[5,6]. In immunocompromised patients CMV 
infection may follow a complicated course resulting 
in retinitis, pneumonia and intestinal disease (mostly 
colitis) or other organ specific disease[7­9]. The role 
of cytomegalovirus (CMV) in inflammatory bowel 
disease (IBD) is under scrutiny. Here, the discussion 
mainly focuses on either the association or causation 
of CMV infection and intestinal disease in adverse 
outcomes in IBD patients. The applied definitions for 
both CMV infection and CMV intestinal disease, are 
crucial in this issue, and the answer to the above key 
question can only be given when there is a unified 
gold standard definition of clinical relevant CMV 
infection and intestinal disease, which is lacking at this 
moment. Our aim was to perform a systematic review 
of the literature to identify the different definitions for 
CMV infection and intestinal disease in IBD patients, 
and to connect the used definitions to the reported 
prevalence. In addition we summarize the different 
diagnostic strategies for CMV infection and intestinal 
disease.
MATERIALS AND METHODS
Search strategy and study selection
A search of the medical literature was conducted using 
MEDLINE, EMBASE and the Cochrane central register 
of controlled trials, until December 2014, according to 
the Preferred Reporting Items for Systematic Reviews 
and Meta­Analyses (PRISMA) guidelines[10,11]. The study 
was registered in the PROSPERO database registry 
(PROSPERO registration number CRD 42015017451). 
The search strategy was designed to identify English­
language (clinical) trials concerning diagnostics and 
prevalence of CMV in IBD. The following medical search 
headings were used: “cytomegalovirus” OR “CMV” 
OR “cytomegalo virus” AND “Inflammatory Bowel 
Disease” OR “IBD” OR “ulcerative colitis” OR “colitis 
ulcerosa” OR “Crohn’s Disease”. Both MeSH­terms and 
free searches were performed. Studies were eligible if 
they reported on prevalence and/or diagnostic criteria 
to define CMV infection or CMV intestinal disease in 
IBD (Table 1).
Because of the paucity of prospective, randomized, 
controlled trials on this subject, we aimed to consider 
all types of evidence available. To this end, we also 
included observational studies, case­control studies 
and retrospective studies. We excluded non­English 
literature, case reports, case series with n < 10 
cases and review articles. We also excluded studies 
that concerned CMV and pouchitis, or studies that 
concerned the causative relationship of CMV and IBD.
Two independent reviewers (Römkens TEH, Bulte 
GJ) performed the first selection, and screened title 
and abstract of the papers identified by electronic 
search. They completed an inclusion form for eligible 
studies. Additional articles were obtained through 
citation snowballing to locate primary sources. When 
no abstract was available, the article was always 
screened by full text. Three investigators read all full 
text papers, and disagreements were resolved by 
consensus (Römkens TEH, Bulte GJ and Nissen LHC).
Outcome assessment
The primary outcomes were: (1) a list with all used 
definitions of CMV infection or CMV intestinal disease 
in IBD patients; and (2) prevalence numbers to 
assess the effect that the applied definition has on 
the reported prevalence of CMV in IBD patients. 
Secondary outcomes were: (1) prevalence of CMV 
in subpopulations as ulcerative colitis (UC), Crohn’s 
disease (CD), steroid refractory disease; and (2) pre­
valence of CMV in different regions of the world. We 
also summarized different diagnostic strategies for 
CMV infection in IBD patients.
Data extraction and assessment of risk of bias
The data extraction process was carried out using a 
pre­established protocol. Full papers were reviewed 
using a purpose­designed database. The following 
clinical data were extracted for each trial: single­ or 
multicenter, country of origin, duration of follow up, 
study period, sample size, characteristics of the studied 
population, medication at baseline, used diagnostics 
for CMV infection, criteria used to define CMV infection, 
criteria used to define CMV intestinal disease, CMV 
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prevalence and authors conclusion. Assessment of 
risk of bias was performed independently by three 
investigators, with disagreements resolved by 
discussion. Risk of bias was assessed by recording 
of study type, retrospective or prospective design, 
sample size, study period and follow up, whether or 
not randomization or blinding was used, and recording 
specific population characteristics that pose a risk for 
selection bias (type and severity of IBD, medication 
use, exclusion criteria).
Statistical analysis
All abstracted data were entered into a structured 
database. We displayed the results for both CMV 
infection and intestinal disease in IBD patients 
separately, in line with the fact that these are two 
different entities. In addition to detailed tables, we 
provide the main results in scatterplots in order to 
give more insight in sample size, median and range 
of the various definitions. Next to this, we provide 
scatterplots of prevalence by definition in different 
subgroups as UC, CD, steroid refractory IBD, and 
IBD patients in different regions of the world. Kappa 
statistics were used to analyze agreement among 
the reviewers. Evidence­tables were provided for all 
characteristics of the included studies. We could not 
carry out a meta­analysis because head­to­head 
comparison of the included studies was impossible due 
to heterogeneity.
RESULTS
Selected studies
Our search strategy generated a total of 924 citations, 
of which 190 (168 + 22) published articles appeared to 
be relevant, and were retrieved for further assessment 
(Figure 1). Of these, 138 (118 + 20) articles were 
excluded for various reasons, leaving 52 eligible 
articles. The main reasons for exclusion were case 
reports; reviews; non­IBD patients; no information on 
CMV (intestinal) infection and non­English literature. 
Agreement in this step between reviewers was 88% 
(Cohen’s Kappa 0.73) before consensus meeting. 
Study (risk of bias) variables are shown in Appendix 1. 
Most of the included studies have small sample sizes. 
None of the included studies was randomized and most 
of the study designs were single centre (n = 42/50) 
with more than half of them using a retrospective 
design (26/48). Some used blinding for the reviewing 
pathologist (6/43) or endoscopist (2/43).
Definitions and prevalence
We identified 21 different definitions for CMV infection, 
and 8 definitions for CMV intestinal disease (Tables 
2 and 3). Three definitions for reactivation of CMV 
are listed in Table 4. Some studies do not mention or 
define CMV infection, but report prevalence numbers 
of “mucosal expression”[12], or “presence of CMV”[13,14] 
and some provide a prevalence rate without defining 
CMV infection[15­62].
Prevalence data for definitions used more than 
once for respectively CMV infection and intestinal 
disease are listed in a scatter plot (Figures 2 and 3).
By using the authors” definition of either CMV 
infection or intestinal disease, we found different 
prevalence numbers in various regions of the world 
and in different subpopulations, which are depicted 
in scatterplots for CMV infection in Figures 4 and 5. 
If available CMV seroprevalence data are depicted 
in Figure 6. More detailed information on this topic 
and prevalence numbers for CMV intestinal disease 
are given in supplementary files (Appendix 2 A, B 
and Appendix 3 A, B). In general, the prevalence 
is negligible in healthy controls. We found a higher 
prevalence in UC than in CD both for CMV infection 
(median 14% vs 2.5%) and CMV intestinal disease 
(median 19.5% vs 11%). The prevalence is highest in 
steroid refractory disease for CMV infection (median 
32.5%) and intestinal disease (median 32.5%).
Diagnostic tests for CMV
More than 10 different tests were used to diagnose 
CMV (active) infection and intestinal disease, which 
can be found in the definition Tables 2 and 3. 
Histology, with or without immunohistochemistry (IHC), 
is most widely used to diagnose CMV disease (infection 
and/or intestinal disease; n = 30/48). PCR on tissue 
is used in almost one third of the included studies 
(14/48). In Table 5 we present an overview of the test 
characteristics as described earlier in literature[24,63­70].
DISCUSSION
This systematic review maps the prevalence of both 
CMV infection and intestinal disease in IBD patients. 
We found that the prevalence greatly depends on 
the used definition. Studies reporting the highest 
prevalence of CMV infection use positive serum PCR as 
test, while studies that use positive antigenemia follow 
suit. In case of diagnosing CMV intestinal disease, the 
highest prevalence applies for tissue PCR (> 10 copies/
mg tissue). IBD patients with steroid refractory disease 
and those coming from East Asia have the highest 
prevalence of CMV infection and/or intestinal disease. 
In general CMV infection or intestinal disease is seen 
more frequently in UC compared to CD.
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Table 1  Eligibility criteria for inclusion
Adults
Diagnosis of IBD, according to international guidelines
English language
Prevalence and/or diagnostics CMV infection or intestinal disease 
reported
Minimal sample size 10 patients
IBD: Inflammatory bowel disease; CMV: Cytomegalovirus.
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seroprevalence studies are lacking, but a review on this 
topic found that seroprevalence tended to be highest 
in South America, Africa and Asia, and was also higher 
in parts of Europe and the Middle East[6]. The most 
likely explanation is the use of different diagnostic 
methods for CMV infection in different regions of the 
world. We show high prevalence numbers for CMV 
infection when antigenemia is used as test (Table 2), 
where 80% of these studies appear to come from 
Japan. CMV infection and more importantly CMV 
colitis is unusual in the healthy population[13,28,29,54] 
as described before in a systematic review[71]. Only 
one study reported presence of CMV DNA in 29% of 
asymptomatic control samples, but robust replication 
studies to confirm this unusual finding are lacking[14]. 
We found lower prevalence of CMV infection (and to 
a lesser extent in intestinal disease) for CD compared 
to UC[13,34] (Appendix 3). The most frequently studied 
population in relation to CMV is those with steroid 
resistant IBD or refractory UC. Apropos it should be 
The difference of CMV infection and clinically 
relevant intestinal disease has been outlined earlier 
in literature. There, CMV infection is described as 
(incidental) finding of positive PCR or detection of 
CMV antigens or antibodies in serum, whereas CMV 
disease is a clinical syndrome where CMV infection is 
accompanied by manifest clinical symptoms[67,69,71,72]. 
Subclinical reactivation of CMV, without symptoms, 
is seen in approximately 50% of active UC cases on 
immunosuppressive therapy[62]. In practice however, 
the different entities described above, are used 
interchangeably. Likewise, no unified definitions have 
been used in clinical trials, and our study documents 
that the terms CMV infection and CMV intestinal 
disease are used reciprocally. This makes it difficult 
to compare data from different studies and to draw 
conclusions for outcome.
Interestingly, by using the author’s definition, we 
found the highest prevalence of CMV infection and 
intestinal disease in East Asia. Population based CMV 
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Initial search: 924 results
Removal of duplicates: 857 left
Selection by title: 216 left
Selection by abstract: 168 left
Selection by full text: 50 left
Reference snowballing: 58 results
Selection by abstract: 22 results
Selection by full text: 2 left
Final selection: 52 results
Excluded:
   Reviews: 15
   Case reports: 31
   Editorials/letters/comments: 281
   Etiology: 2
   No CMV colitis or IBD: 19
   No prevalence: 20
   Duplicates: 3
   Total: 118
Excluded:
   No CMV colitis: 3
   No IBD: 9
   Case reports: 3
   Non-English: 1
   Congress abstract: 1
   Duplicates: 1
   Guidelines: 2 
   Total: 20
Figure 1  Algorithm of inclusion. 1Letters/comments presenting original data were included in the review. 
Römkens TEH et al . CMV in IBD: A systematic review
noted that these studies use different definitions for 
steroid resistant IBD or refractory UC which may affect 
the prevalence[71,73]. We found the highest prevalence 
of CMV infection and CMV intestinal disease in steroid 
refractory disease, for each definition of CMV used[54] 
(Appendix 3). Whether or not CMV reactivation has a 
role in the process of steroid resistance, is still under 
debate[57,73­75].
The surveyed literature contains 29 different 
methods to diagnose CMV infection and/or intestinal 
disease, probably mainly caused by the fact that still no 
single gold standard exists for (clinically relevant) CMV 
infection in IBD. In general, the literature recommends 
to process biopsies for HE and IHC[33,63,71,76] and/or if 
available by CMV DNA real­time PCR, with a cut off 
value that is yet to be identified[76]. The recent ECCO 
guideline[72] mentions that different techniques for 
diagnosis of CMV infection are available, but stops 
short of defining a gold standard. The guideline 
refers to histopathology combined with IHC (using 
monoclonal antibodies) as highly specific and sensitive 
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Table 2  Prevalence by definition of cytomegalovirus-infection
Definition Studies, n Median Range
Antigenemia[17-21] 5 32%   6%-34%
Tissue PCR[22-25] 4 11%   1%-32%
IHC1[26-29] 4 13%   9%-23%
HE[30-32] 3 17%   5%-36%
HE or IHC[33,34] 2   8%   5%-11%
HE and IHC[35, 36] 2 19% 12%-27%
IgM or HE or IHC2[37,38] 2   9%   5%-13%
Antigenemia or Tissue PCR[39] 1 NA NA
Serum PCR[40] 1 84% -
(HE and IHC) or tissue PCR[41] 1   4% -
Tissue PCR 10 copies/µg; OR histology OR Antigenemia[42] 1 54% -
Antigenemia (2 tests: C7-HRP OR C10/C11) OR histology[43] 1   9% -
Antigenemia or blood PCRquantitative[44] 1 36% -
IgM or serum PCR or HE[45] 1 78% -
IgM or tissue PCRqualitative or HE[46] 1 16% -
IgG and (blood culture, antigenemia or histology or IgM or urine culture)[47] 1   6% -
IgM or serum PCRqualitative or feces PCR[48] 1   5% -
Inclusions: HE[49] 1 13% -
Active infection: tissue PCR[50] 1 13% -
Active replication: (HE or IHC) and antigenemia[51] 1 36% -
Blood dissemination: (viremia, antigenemia, RNAemia) or (viremia or tissue culture)[52] 1 16% -
Total: 21 Total: 36
1One study defined a clinically relevant infection as > 10 IHC + cells/section but also recognized “scattered” positivity as 1-9 cells per section[29]; 2Once 
mentioned as “acute infection”. PCR: Polymerase chain reaction; HE: Hematoxylin and eosin staining; IHC: Immunohistochemistry; IgM: Immunoglobulin 
M; IgG: immunoglobulin G; NA: Not applicable.
Table 3  Prevalence by definition of cytomegalovirus-intestinal disease
Definition Studies, n Median Range
HE or IHC1,2[38,44,53,54] 4   6%   2%-29%
HE[20,55] 2   9%   0%-17%
Tissue PCRquantitative > 10 copies/mg[56, 57] 2 34% 30%-38%
Serology and (IHC or antigenemia or serum PCR or tissue PCR)[58] 1   6% -
IHC[59] 1   0% -
HE or IHC or tissue PCR[51] 1 33% -
(Pp65 antigenemia or tissue PCRquantitative) and IHC and intestinal symptoms[39] 1 NA3 -
IHC positive when inflammation present[52] 1   1% -
Total: 8 Total: 13
1One study tested both before and after iv-steroid administration; 2No data on prevalence: definition is used as the gold standard to compare other 
diagnostics; 3No prevalence is reported in this study. PCR: Polymerase chain reaction; HE: Hematoxylin and eosin staining; IHC: Immunohistochemistry.
Table 4  Prevalence by definition of cytomegalovirus-
reactivation
Definition Studies, n Median Range
IgM or HE or PCR1[60] 1 10% -
Serum PCR in IgG positive 
patients[61]
1   0% -
Antigenemia or plasma PCR[62] 1 36% -
Total: 3 Total: 3
1Not specified what material is used for PCR testing. PCR: Polymerase 
chain reaction; HE: Hematoxylin and eosin staining; IgM: Immunoglobulin 
M; IgG: Immunoglobulin G.
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for verifying CMV infection in tissue. In addition the 
guideline describes quantitative PCR in tissue and in 
blood as the most commonly used and advantageous 
technique for diagnosis of CMV infection. Quantitative 
PCR has a low sensitivity for diagnosing CMV colitis 
in patients with moderate to severe UC, and cannot 
substitute histopathology diagnosis[44]. Already in the 
nineties consensus meetings were held to formulate 
the definition for CMV infection in general and for all 
organ specific involvements in transplant recipients. 
These definitions were updated again in 2002[67]. CMV 
infection was defined as isolation of the CMV virus or 
detection of viral proteins or nucleic acid in any body 
fluid or tissue specimen. There CMV (gastro)intestinal 
disease was defined by identification of a combination 
of (1) clinical symptoms; (2) findings of macroscopic 
mucosal lesions on endoscopy; and (3) demonstration 
of CMV infection (by culture, histopathology, IHC, or in 
situ hybridization) in a (gastro)intestinal tract biopsy 
specimen. According to this guideline detection of 
CMV by PCR alone is insufficient for diagnosis of CMV 
gastrointestinal disease. Applying these criteria to IBD 
patients can be more complicated, since ulceration 
can also be caused by the underlying IBD. Since then, 
multiple more sensitive diagnostic tests have been 
developed to detect CMV, but a threshold or definition 
of clinical relevant CMV infection or intestinal disease 
remains to be established. We suggest that a global 
multidisciplinary consensus meeting on CMV and 
IBD should be held, in order to develop one unified 
definition of clinically relevant CMV intestinal disease. 
In this context, clinically relevant describes the 
situation that symptoms appear, clinical deterioration 
occurs, and (antiviral) treatment should be initiated. 
This single definition could be used in clinical practice, 
but also in future trials, to serve as a gold standard 
in the discussion on outcome and optimal (antiviral) 
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Figure 2  Prevalence cytomegalovirus infection by authors definition. Size 
of the squares corresponds with the population size in 5 categories (n = 0-25, n 
= 25-50, n = 50-100, n = 100-250, n > 250). Median depicted as dotted line.
Tissue PCR >10 
copies/mg
HE
HE or IHC
0       10       20      30       40       50  60 70 80 90 100
                           Prevalence (%)
Figure 3  Prevalence cytomegalovirus intestinal disease by authors 
definition. Size of the squares corresponds with the population size in 5 
categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 250). Median 
depicted as dotted line.
Central Asia
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Figure 4  Prevalence cytomegalovirus infection in different global regions 
by authors definition. Size of the squares corresponds with the population 
size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 250). 
Median depicted as dotted line.
50 60 70 80 90 10
0
Figure 5  Prevalence cytomegalovirus infection in different sub 
populations, by authors definition. Size of the squares corresponds with the 
population size in 5 categories (n = 0-25, n = 25-50, n = 50-100, n = 100-250, n 
> 250). Median depicted as dotted line.
Resection steroid 
refractory 
Surgical resection 
specimens
Steroid refractory 
IBD
Crohn's disease
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IBD
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Figure 6  Cytomegalovirus seroprevalence data in different regions of the 
world. Size of the squares corresponds with the population size in 5 categories 
(n = 0-25, n = 25-50, n = 50-100, n = 100-250, n > 250). Median depicted as 
dotted line.
0 10 20 30 40
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treatment of CMV in IBD patients.
Our study has several strengths. First of all, we 
show that the use of different definitions of CMV 
infection impacts reported prevalence rates. Second, 
we provide CMV prevalence data for several important 
sub populations, as UC, CD, steroid refractory disease, 
and patients in different continents of the world. 
Third, two independent reviewers reviewed all eligible 
studies, and three reviewers read all full text papers, 
with good agreement scores based on the presented 
kappa value. Our study comes with some limitations. 
None of the included studies were randomized, most 
of them had a retrospective design and only some 
used blinding of endoscopists or pathologists. The 
heterogeneity of the design of included studies and 
wide variations in used definitions for both CMV 
infection and intestinal disease made it impossible to 
perform a meta­analysis on these data.
In conclusion we find a wide variety in definitions 
used for CMV infection and intestinal disease in IBD 
patients, which impacts corresponding prevalence 
rates and eventually the outcome in different trials. 
A global consensus meeting is pivotal to develop one 
unified gold standard definition for clinically relevant 
CMV, to be used in clinical practice as well as in future 
trials.
COMMENTS
Background
Cytomegalo virus (CMV) infection is common, but mostly asymptomatic in the 
general population. In immunocompromised patients CMV infection may result 
in complications and organ-specific disease such as colitis. The exact role of 
CMV in clinical deterioration in inflammatory bowel disease (IBD) patients under 
debate. There is no global consensus on definitions of clinically relevant CMV 
disease in IBD patients.
Research frontiers
The optimal treatment strategy of refractory IBD, involving CMV infection, 
remains to be determined. Various treatment options, as the use of antiretroviral 
agents or intensified immunosuppressive therapy are being studied. It is 
most likely that the outcomes of the different trials will be influenced by the 
used definition of CMV infection and intestinal disease. Therefore one unified 
definition is essential.
Innovations and breakthroughs
Multiple diagnostic tests circulate to diagnose CMV infection. As a result, more 
than 20 definitions are used in clinical practice and for research purposes. This 
review is the first to address this challenging issue and the problems resulting 
from like the interpretation of study outcomes on this topic.
Applications
A global consensus meeting is necessary to determine one unified definition for 
CMV infection and intestinal disease in IBD to be used in clinical practice and 
future research.
Terminology
CMV-infection: systemic presence of viral antigens or replication markers. 
CMV-intestinal disease: evidence of viral presence in intestinal tissue. Steroid 
refractory disease: IBD not responding to treatment with high dose intravenous 
corticosteroids.
Peer-review
This is an interesting and timely manuscript addressing a significant 
discrepancy between the different definitions of CMV disease in IBD.
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